Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oncopeptides AB ( (SE:ONCO) ) has shared an announcement.
Oncopeptides AB announced new clinical and real-world evidence for its multiple myeloma drug Pepaxti, to be presented at the COMy congress in Paris. The data package includes a large Spanish real-world registry, a pooled renal safety analysis and an update from the ongoing LAGOON non-interventional study.
The Spanish Registry, covering 60 heavily pretreated patients, showed a 40% overall response rate that rose to 45.4% in those previously treated with novel immunotherapies, along with survival outcomes consistent with earlier HORIZON trial results. Pepaxti also served as an effective bridge to CAR-T therapy in select cases, underscoring its potential role in complex treatment sequences.
Pooled data from three trials involving 430 patients indicated that renal function remained stable during melflufen therapy and renal adverse events were uncommon, supporting its use in patients with mild to moderate renal impairment. The LAGOON study, enrolling 50 adults in Spain, is expected to provide further real-world effectiveness and safety insights that could strengthen Pepaxti’s positioning in the European multiple myeloma treatment landscape.
More about Oncopeptides AB
Oncopeptides AB is a Stockholm-based biotechnology company specializing in therapies for difficult-to-treat cancers, with a current focus on relapsed refractory multiple myeloma. Its lead product Pepaxti (melflufen) is positioned as a treatment option for heavily pretreated patients in Europe, targeting segments with high unmet medical need in hematologic oncology.
Average Trading Volume: 3,305,823
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK494.9M
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.